Drug intelligence / Profile preview

phospholimab

Development stage: Preclinical
Lead developer: Evexta Bio
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

Phospholimab, also known as Plazumab or DIACC1010, is a humanized monoclonal antibody developed by the French biotech company Diaccurate, created by Truffle Capital. It was developed under an exclusive worldwide license from Institut Pasteur, based on the discovery of the role of the PLA2G1B enzyme in HIV infection. Phospholimab works by neutralizing the PLA2G1B enzyme, which is known to contribute to the disablement of CD4+ T-cells in HIV patients. The drug's primary goal is to restore immune function in individuals with HIV and potentially other diseases.

Brand names: Plazumab
Other names: phospholimab

Targets

PLA2G1B (Phospholipase A2 group IB)

Beyond the preview

Go deeper on phospholimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on phospholimab.

Explore the full profile